Secondary Logo

Most Popular Articles

Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY

Potkin, Steven G.; Loze, Jean-Yves; Forray, Carlos; More

International Clinical Psychopharmacology. 32(3):147-154, May 2017.

The effect of selective serotonin reuptake inhibitors on major adverse cardiovascular events: a meta-analysis of randomized-controlled studies in depression

Kim, YongHwan; Lee, Young Sook; Kim, Myeong Gyu; More

International Clinical Psychopharmacology. 34(1):9-17, January 2019.

Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder

Boulenger, Jean-Philippe; Loft, Henrik; Olsen, Christina Kurre

International Clinical Psychopharmacology. 29(3):138-149, May 2014.

The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies

Weiss, Catherine; Weiller, Emmanuelle; Baker, Ross A.; More

International Clinical Psychopharmacology. 33(5):255-260, September 2018.

Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control

Kasper, Siegfried; Corruble, Emmanuelle; Hale, Anthony; More

International Clinical Psychopharmacology. 28(1):12-19, January 2013.

Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study

Jacobsen, Paula L.; Harper, Linda; Chrones, Lambros; More

International Clinical Psychopharmacology. 30(5):255-264, September 2015.

Effects of vilazodone on sexual functioning in healthy adults: results from a randomized, double-blind, placebo-controlled, and active-controlled study

Clayton, Anita H.; Durgam, Suresh; Li, Dayong; More

International Clinical Psychopharmacology. 32(1):27-35, January 2017.

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies

Earley, Willie; Durgam, Suresh; Lu, Kaifeng; More

International Clinical Psychopharmacology. 32(6):319-328, November 2017.

Outcome and predictors of remission in bipolar-I patients experiencing manic episode and treated with oral antipsychotics and/or mood stabilizers: a prospective observational study in Italy

Perugi, Giulio; Vannucchi, Giulia; Barbuti, Margherita; More

International Clinical Psychopharmacology. 33(3):131-139, May 2018.

Proinflammatory and anti-inflammatory biomarkers in schizophrenia and influence of simvastatin on the interleukin-6

Francesconi, Lenise P.; Victorino, André T.; Salah, Iarsan A.; More

International Clinical Psychopharmacology. 34(2):84-88, March 2019.

Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union

Brody, Robert S.; Liss, Charles L.; Wray, Heather; More

International Clinical Psychopharmacology. 33(2):59-65, March 2018.

Patient adherence and efficacy of quetiapine treatment in schizophrenia: results of a multicentre, naturalistic 6-month follow-up study

Alptekin, Koksal; Aydin, Hamdullah; Gucer, Kadri M.; More

International Clinical Psychopharmacology. 25(6):342-348, November 2010.

Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate

Montalvo, Itziar; Ortega, Laura; López, Xavi; More

International Clinical Psychopharmacology. 28(1):46-49, January 2013.

Relapse prevention in adults with major depressive disorder treated with vilazodone: a randomized, double-blind, placebo-controlled trial

Durgam, Suresh; Gommoll, Carl; Migliore, Raffaele; More

International Clinical Psychopharmacology. 33(6):304-311, November 2018.

Comparison of escitalopram and paroxetine in the treatment of major depressive disorder

Lin, Huang-Li; Hsu, Ya-Ting; Liu, Chia-Yih; More

International Clinical Psychopharmacology. 28(6):339-345, November 2013.

D-cycloserine does not enhance exposure–response prevention therapy in obsessive–compulsive disorder

Storch, Eric A.; Merlo, Lisa J.; Bengtson, Michael; More

International Clinical Psychopharmacology. 22(4):230-237, July 2007.

Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome

Farabaugh, Amy H.; Bitran, Stella; Witte, Janet; More

International Clinical Psychopharmacology. 25(4):214-217, July 2010.

The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study

Montgomery, Stuart A.; Mansuy, Lucilla; Ruth, Adam C.; More

International Clinical Psychopharmacology. 29(1):26-35, January 2014.

Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression

Thase, Michael E.; Nierenberg, Andrew A.; Vrijland, Peter; More

International Clinical Psychopharmacology. 25(4):189-198, July 2010.

Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive–compulsive disorder?

Benatti, Beatrice; Camuri, Giulia; Dell’Osso, Bernardo; More

International Clinical Psychopharmacology. 31(6):347-352, November 2016.

Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics

Kwon, Jun Soo; Kim, Sung Nyun; Han, Jaewook; More

International Clinical Psychopharmacology. 30(6):320-328, November 2015.

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

Boyer, Patrice; Montgomery, Stuart; Lepola, Ulla; More

International Clinical Psychopharmacology. 23(5):243-253, September 2008.

Show: